Oculus Innovative Sciences, Inc. Completes Patient Enrollment in Study of Microcyn® Hydrogel in Management of Scars
Published: Nov 14, 2012
PETALUMA, Calif., Nov. 14, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced it has completed patient enrollment in its double-blind, randomized clinical study evaluating an advanced Microcyn® hydrogel for management of hypertrophic and keloid scars under an FDA-reviewed protocol. The data from the 40-patient trial, which includes patient treatment and eight weeks of follow-up, will be submitted to the FDA in 2013, with FDA clearance and commercialization expected later that year. Patients were recruited at four different U.S. sites: Albuquerque, NM, High Point, NC, Austin, TX and College Station, TX.